



Sodium Valproate for the Epigenetic Reprogramming of High-Risk Oral Epithelial Dysplasia

Trial Launch Event

(Accredited by the Royal College of Surgeons of England for up to 3.0 CPD points)

Tuesday 29th November

University of Liverpool Cancer Research Centre

AGENDA:	
10:30	Registration and refreshments
11:00	Session 1 <ul style="list-style-type: none"> 11:00 - 11:15 Management of OED <i>Dr Stefano Fedele, University College London</i> 11:15 - 11:30 Trial design in oral chemoprevention studies <i>Professor Richard Shaw, University of Liverpool</i> 11:30 - 11:45 Allelic Imbalance and epigenetics in oral SCC: a basic explainer <i>Dr Lakis Liloglou, University of Liverpool</i> 11:45 - 12:00 Epigenetic therapies, Sodium Valproate in cancer studies and Kang study <i>Dr Joe Sacco, University of Liverpool</i> 12:00 - 12:15 Patients' perspective in oral premalignancy <i>Mrs Margaret Daunt, Patient representative</i> 12:15 - 12:30 Q&A <i>Dr Stefano Fedele</i>
12:30	Lunch
13:15	Session 2 <ul style="list-style-type: none"> 13:15—13:25 SAVER trial design overview <i>Professor Richard Shaw</i> 13:25—13:35 Pathology of OED and composite endpoint <i>Dr Max Robinson, University of Newcastle upon Tyne</i> 13:35—13:45 Mechanistic sub-study <i>Dr Lakis Liloglou</i> 13:45—13:55 Qualitative sub-study <i>Professor Bridget Young, University of Liverpool</i> 13:55—14:05 Requirements, demands and practicalities of PI's & sites <i>SAVER Trial Management Group</i>
14:05	Session 3 - Chaired by Professor Richard Shaw <ul style="list-style-type: none"> Comments from sites Remaining work prior to study initiation Q&A 15:00 Close

